Renée Winsky, president and executive director of the Maryland Technology Development Corporation, will resign from her position effective August 28, TEDCO said last week.
John Wasilisin, current vice president and chief operating officer, will be appointed acting president and executive director of TEDCO following Winsky's departure, while the organization conducts a national search for Winsky's replacement.
Winsky is leaving TEDCO to become CEO of the Tech Council of Maryland, the state's largest trade group for the technology and biotechnology communities. She replaces Julie Coons, who stepped down as CEO of TCM late last year.
During her time as TEDCO's president and executive director, Winsky helped establish the Maryland Stem Cell Research Fund; the first-ever partnership intermediary agreement with the US Department of Agriculture's Agriculture Research Service; and the TechStart program. She has also served for the last two years on Governor Martin O'Malley's Maryland Life Sciences Advisory Board.
Before assuming her most recent role with TEDCO, Winsky served as deputy executive director of the organization for seven years. Before that, she was vice president of the information technology services division of the Information Technology Association of America. She has also worked with the National League of Cities and its affiliate, the National Association of Telecommunications Officers and Advisors.
Washington University in St. Louis said this week that Evan Kharasch has been named interim vice chancellor for research.
Kharasch, a professor of anesthesiology and biochemistry and molecular biophysics at the WUSTL School of Medicine, succeeds Samuel Stanley, who left the university on June 30 to become president of the State University of New York at Stony Brook.
As interim vice chancellor, Kharasch will be responsible for the university's research mission, including development of research policies, management of grants and contracts, continuing education of faculty and staff regarding research regulations, issues of conflict of interest, and intellectual property and technology transfer.
Kharasch has directed the department of anesthesiology's division of clinical and translational research at WUSTL since 2005, when he joined the university from the University of Washington in Seattle. He holds a bachelor's degree in medical sciences, a PhD in pharmacology, and an MD from Northwestern University. He also completed an internship, residency, and research fellowship in anesthesiology at UW before joining its faculty in 1988.
Life sciences VC firm Third Rock Ventures said this week that it has appointed Philip Reilly and Gregory Verdine as venture partners, and Craig Greaves as recruiting partner.
Reilly served as CEO and chairman of Interleukin Genetics from 2000 to 2006. Prior to that, he was executive director of non-profit group the Eunice Kennedy Shriver Center for Mental Retardation. Reilly has held numerous teaching positions including assistant professor at Tufts University School of Medicine; assistant professor of neurology at Harvard Medical School; and adjunct professor of legal studies and biology at Brandeis University.
Verdine is currently director of the chemical biology initiative and program in cancer chemical biology at the Dana-Farber Cancer Institute, and is a Harvard College professor and a professor of chemistry at Harvard University. Verdine was a founding scientific advisor to Vertex Pharmaceuticals; and co-founded Enanta Pharmaceuticals, Gloucester Pharmaceuticals, Aileron Therapeutics, Tokai Pharmaceuticals, and Ontorii Pharmaceuticals.
Greaves most recently served as director of talent acquisition at Cubist Pharmaceuticals. Previously, he was director of employment at Biogen Idec, having transitioned to the company after a nine-year career with Biogen.
The Cancer Prevention and Research Institute of Texas said this week that it has named Kristen Pauling Doyle as general counsel.
Doyle most recently served as principal attorney at an unnamed Austin-based law firm, CPRIT said. Prior to that, she was an assistant public counsel for the Texas Office of Public Utility Counsel.
Doyle holds a bachelor's degree in public policy from Indiana University and a JD from the University of Texas School of Law at Austin.
Daniel Von Hoff, physician in chief of the Translational Genomics Institute and executive vice president of TGen's Translational Drug Development Division, has been named to the scientific advisory board of InNexus Biotechnology, the company said last week.
Von Hoff has also served as professor of medicine, molecular, and cellular biology and pathology at the University of Arizona; chief scientific officer for US Oncology; and president of the American Association of Cancer Research.
Von Hoff earned his MD from Columbia University College of Physicians and Surgeons.
Frank Hoy has joined the faculty of the Worcester Polytechnic Institute as the inaugural Paul R. Beswick Professor of Entrepreneurship in the university's department of management.
Hoy will also serve as director of WPI's Collaborative for Entrepreneurship and Innovation.
Hoy most recently served as director of the Centers for Entrepreneurial Development, Advancement, Research, and Support at the University of Texas at El Paso. He holds a bachelor's degree in business administration from UTEP, an MBA from the University of North Texas, and a PhD in management from Texas A&M University.